Key Highlights
- Vaxcyte shares rose about 5.87% to $63.30, leaving the stock roughly 2.6% below its 52-week high near $64.99.
- No single Vaxcyte-specific news item was found dated today; the move appears tied to a broader Vaccine and biotech sector lift following Moderna and Merck's positive Phase 3 melanoma-vaccine trial data, layered on Vaxcyte's own strong clinical and balance-sheet position.
- RSI of 66.7 reflects a strong up technical trend without yet reaching overbought territory.
- Vaxcyte reported all three adult Phase 3 OPUS trials for its lead candidate VAX-31 fully enrolled as of its August 5, 2026 second-quarter update, with topline data from OPUS-1 expected in the fourth quarter of 2026 and $2.51 billion in cash on hand.
Vaccine-Sector Rally Coincides With Pipeline Progress
Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine developer, rose roughly 5.87% on August 20, 2026, moving to within about 2.6% of its 52-week high. The specific move does not appear to be tied to a distinct same-day Vaxcyte press release; rather, it coincides with a broader rally across vaccine and biotech names after Moderna and Merck disclosed positive Phase 3 data for their mRNA melanoma vaccine on August 19, 2026, a result widely described as validating for the vaccine-development field generally. That sector tailwind lands on top of Vaxcyte's own recent operational momentum in its 31-valent pneumococcal conjugate vaccine candidate, VAX-31.
Fully Enrolled Phase 3 Program and Strong Cash Position
In its second-quarter 2026 results, reported August 5, 2026, Vaxcyte disclosed that all three of its adult Phase 3 OPUS trials evaluating VAX-31 for prevention of invasive pneumococcal disease and pneumonia were fully enrolled, covering 6,191 participants, with topline data from OPUS-1 expected in the fourth quarter of 2026. The company also disclosed a strong balance sheet, with cash, cash equivalents and investments totaling $2.51 billion as of June 30, 2026, and had begun a Phase 1 study for a separate candidate, VAX-A1, targeting Group A Strep. Earlier in 2026, Phase 1/2 adult VAX-31 data published in The Lancet Infectious Diseases showed the candidate met or exceeded non-inferiority versus a competitor vaccine for 20 shared serotypes.
Momentum Intact but Unprofitable and Data-Dependent
Vaxcyte's RSI of 66.7 indicates strong upward momentum without being technically overbought, unlike some peers in this rally. Analyst price targets remain wide-ranging, with an average around $109 and a high near $163 as of mid-August 2026, though the company remains unprofitable, with net losses continuing as it funds late-stage trials. Because near-term share performance appears more closely tied to sector sentiment than to a distinct company announcement today, the stock's ability to hold these gains may depend heavily on the eventual OPUS-1 topline readout expected later in 2026, which represents Vaxcyte's next major binary catalyst.
What Investors Should Watch
Vaxcyte is trading about 2.6% below its 52-week high after riding a broader vaccine-sector rally sparked by Moderna and Merck's melanoma-vaccine trial success, layered on the company's own fully enrolled Phase 3 VAX-31 program and $2.51 billion cash position. These are the verified facts as reported. Whether the rally holds may depend on newsflow around the pending OPUS-1 Phase 3 topline data expected in the fourth quarter of 2026, since no distinct Vaxcyte-specific catalyst dated today was identified.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...